Patents Assigned to PEGBIO CO., LTD.
  • Publication number: 20240277816
    Abstract: The present invention belongs to the field of medicine, and the present invention relates, in particular, to a polypeptide conjugate and an application of a polypeptide conjugate in the preparation of a drug for treating diseases related to glucose metabolism. The polypeptide conjugate of the present invention is formed by conjugating a glucagon mutant with one or more polyethylene glycols. The polypeptide conjugate can rapidly increase the blood glucose level within the body and maintain for a long time a stable blood glucose level within the body. The present invention is suitable for the treatment of congenital hyperinsulinism and various types of hypoglycemic disorders.
    Type: Application
    Filed: July 20, 2022
    Publication date: August 22, 2024
    Applicant: PegBio Co., Ltd.
    Inventors: Min XU, Yinghui ZHANG
  • Patent number: 10894076
    Abstract: The present invention provides a composition comprising a GLP-1 receptor agonist and a glucagon receptor agonist and an application of the composition. More specifically, the present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of the GLP-1 receptor agonist and the glucagon receptor agonist, wherein the GLP-1 receptor agonist and the glucagon receptor agonist independently form a conjugate with a hydrophilic polymer, or the GLP-1 receptor agonist and the glucagon receptor agonist jointly form a conjugate with the hydrophilic polymer.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: January 19, 2021
    Assignee: PEGBIO CO., LTD.
    Inventors: Michael Min Xu, Wei Lv, Yinghui Zhang, Xiaosu Luo
  • Publication number: 20190134161
    Abstract: The present invention provides a composition comprising a GLP-1 receptor agonist and a glucagon receptor agonist and an application of the composition. More specifically, the present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of the GLP-1 receptor agonist and the glucagon receptor agonist, wherein the GLP-1 receptor agonist and the glucagon receptor agonist independently form a conjugate with a hydrophilic polymer, or the GLP-1 receptor agonist and the glucagon receptor agonist jointly form a conjugate with the hydrophilic polymer.
    Type: Application
    Filed: December 28, 2016
    Publication date: May 9, 2019
    Applicant: PEGBIO CO., LTD.
    Inventors: Michael Min Xu, Wei Lv, Yinghui Zhang, Xiaosu Luo
  • Patent number: 8575097
    Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: November 5, 2013
    Assignee: Pegbio Co., Ltd.
    Inventors: Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou
  • Publication number: 20120196795
    Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.
    Type: Application
    Filed: April 23, 2010
    Publication date: August 2, 2012
    Applicant: PEGBIO CO., LTD.
    Inventors: Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou